Disruption of arginase II alters prostate tumor formation in TRAMP mice

Prostate

Volumn 68, Issue 14, 2008, Pages 1561-1569

  Mumenthaler, Shannon M ^a   Rozengurt, Nora ^a   Livesay, Justin C ^a   Sabaghian, Anahita ^a   Cederbaum, Stephen D ^a   Grody, Wayne W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arginase II; Knockout mice; Polyamines; Prostate cancer; TRAMP (transgenic adenocarcinoma of mouse prostate)

Indexed keywords

ARGINASE; ARGINASE 2; UNCLASSIFIED DRUG; ARG2 PROTEIN, MOUSE; DEATH RECEPTOR 3; RNA; TNFRSF25 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CARCINOGENESIS; CONTROLLED STUDY; CROSS BREEDING; GENITAL SYSTEM; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; URINARY TRACT; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHEMISTRY; ENZYMOLOGY; GENETICS; METABOLISM; MOUSE MUTANT; NEOPLASM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ARGINASE; BLOTTING, WESTERN; CELL LINE, TUMOR; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 51649093103     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20816     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66.
2. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000;14(19):2410-2434.
3. Devens BH, Weeks RS, Burns MR, Carlson CL, Brawer MK. Polyamine depletion therapy in prostate cancer. Prostate Cancer Prostatic Dis 2000;3(4):275-279.
4. Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol 1982;243(5):C212-C221.
5. Russell DH. Polyamines and prostatic function. Prog Clin Biol 75:207-224.
6. Jenkinson CP, Grody WW, Cederbaum SD. Comparative properties of arginases. Comp Biochem Physiol B Biochem Mol Biol 1996;114(1):107-132.
7. Li H, Meininger CJ, Kelly KA, Hawker JR Jr, Morris SM Jr, Wu G. Activities of arginase I and II are limiting for endothelial cell proliferation. Am J Physiol Regul Integr Comp Physiol 2002;282(1):R64-69.
8. Li H, Meininger CJ, Hawker JR Jr, Haynes TE, Kepka-Lenhart D, Mistry SK, Morris SM Jr, Wu G. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 2001;280(1):E75-82.
9. Vockley JG, Jenkinson CP, Shukla H, Kern RM, Grody WW, Cederbaum SD. Cloning and characterization of the human type II arginase gene. Genomics 1996;38(2):118-123.
10. Mumenthaler SM, Yu H, Tze S, Cederbaum SD, Pegg AE, Seligson DB, Grody WW. Expression of arginase II in prostate cancer. Int J Oncol 2008;32(2):357-365.
11. Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, Battistini L, Iafrate M, Prayer-Galetti T, Pagano F, Viola A. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 2005;201(8):1257-1268.
12. Keskinege A, Elgun S, Yilmaz E. Possible implications of arginase and diamine oxidase in prostatic carcinoma. Cancer Detect Prev 2001;25(1):76-79.
13. Chang CI, Liao JC, Kuo L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res 2001;61(3):1100-1106.
14. Elgun S, Keskinege A, Yilmaz E, Baltaci S, Beduk Y. Evaluation of serum arginase activity in benign prostatic hypertrophy and prostatic cancer. Int Urol Nephrol 1999;31(1):95-99.
15. Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G. Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res 2000;60(12):3305-3312.
16. Cederbaum SD, Yu H, Grody WW, Kern RM, Yoo P, Iyer RK. Arginases I and II: do their functions overlap? Mol Genet 81(Suppl 1):S38-S44.
17. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92(8):3439-3443.
18. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56(18):4096-4102.
19. Sharma P, Schreiber-Agus N. Mouse models of prostate cancer. Oncogene 1999;18(38):5349-5355.
20. Shi O, Morris SM Jr, Zoghbi H, Porter CW, O'Brien WE. Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene. Mol Cell Biol 2001;21(3):811-813.
21. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55(3):219-237.
22. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64(6):2270-2305.
23. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997;57(16):3325-3330.
24. Mendez JD, Sosa A, Palomar-Morales M. Effect of L-arginine on arginase activity in male accessory sex glands of alloxan-treated rats. Reprod Toxicol 2002;16(6):809-813.
25. Yamanaka H, Kirdani RY, Saroff J, Murphy GP, Sandberg AA. Effects of testosterone and prolactin on rat prostatic weight, 5alpha-reductase, and arginase. Am J Physiol 1975;229(4):1102-1109.
26. Manteuffel-Cymborowska M, Chmurzynska W, Peska M, Grzelakowska-Sztabert B. Arginine and ornithine metabolizing enzymes in testosterone-induced hypertrophic mouse kidney. Int J Biochem Cell Biol 1995;27(3):287-295.
27. Levillain O, Diaz JJ, Blanchard O, Dechaud H. Testosterone down-regulates ornithine aminotransferase gene and up-regulates arginase II and ornithine decarboxylase genes for polyamines synthesis in the murine kidney. Endocrinology 2005;146(2):950-959.
28. Rui H, Brekke I, Morkas L, Purvis K. Androgen interaction with the polyamine system of the rat prostate. Andrologia 1987;19(2):134-142.
29. Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, Belldegrun AS. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 2003;55(1):71-80.
30. Kee K, Foster BA, Merali S, Kramer DL, Hensen ML, Diegelman P, Kisiel N, Vujcic S, Mazurchuk RV, Porter CW. Activated polyamine catabolism depletes acetyl-CoA pools and suppresses prostate tumor growth in TRAMP mice. J Biol Chem 2004;279(38):40076-40083.
31. Holtta E, Pohjanpelto P. Polyamine dependence of Chinese hamster ovary cells in serum-free culture is due to deficient arginase activity. Biochim Biophys Acta 1982;721(4):321-327.
32. Oka T, Perry JW. Arginase affects lactogenesis through its influence on the biosynthesis of spermidine. Nature 1974;250(5468):660-661.
33. Mitchell GA, Looney JE, Brody LC, Steel G, Suchanek M, Engelhardt JF, Willard HF, Valle D. Human ornithine-delta-aminotransferase. cDNA cloning and analysis of the structural gene. J Biol Chem 1988;263(28):14288-14295.
34. Zintz CB, Inana G. Analysis of the human ornithine amino-transferase gene family. Exp Eye Res 1990;50(6):759-770.
35. Peraino C, Bunville LG, Tahmisian TN. Chemical, physical, and morphological properties of ornithine aminotransferase from rat liver. J Biol Chem 1969;244(9):2241-2249.
36. Wang T, Lawler AM, Steel G, Sipila I, Milam AH, Valle D. Mice lacking ornithine-delta-aminotransferase have paradoxical neonatal hypoornithinaemia and retinal degeneration. Nat Genet 1995;11(2):185-190.
37. Hayashi T, Matsufuji S, Hayashi S. Characterization of the human antizyme gene. Gene 1997;203(2):131-139.
38. Kramer DL, Sufrin JR, Porter CW. Modulation of polyamine-biosynthetic activity by S-adenosylmethionine depletion. Biochem J 1988;249(2):581-586.